Groups | Â | Treatment condition |
---|---|---|
1 | Healthy control | Weekly IP normal saline for 15 weeks/Normal saline gavage weekly for weeks 16–23 |
2 | Placebo | DMH** (20 mg/Kg, I.P.) weekly for 15 weeks/Normal Saline Gavage Placebo for weeks 16–23 |
3 | Nanocarrier | DMH (20 mg/Kg, I.P.) weekly for 15 weeks/Blank Nanocarrier for weeks 16–23 |
4 | 5-FU | DMH (20 mg/Kg, I.P.) weekly for 15 weeks/25 mg/Kg 5-FU for weeks 16–23 |
5 | BA-Ex | DMH (20 mg/Kg, I.P.) weekly for 15 weeks/100 mg/Kg BA-Ex for weeks 16–23 |
6 | Nano-BA-Ex | DMH (20Â mg/Kg, I.P.) weekly for 15Â weeks/100Â mg/Kg Nano-BA-Ex for weeks 16 to 23 |
7 | Nano-BA-Ex/5-FU | DMH (20 mg/Kg, I.P.) weekly for 15 weeks/100 mg/Kg Nano-BA-Ex + 25 mg/Kg 5-FU for weeks 16–23 |